Pharmaceutical Non-Active Ingredients TRIZ Cases

Halogenated methionine peptides resist oxidation to maintain stability while activating innate immune cells against tumors.

Reversibly bonded hydrophilic polymers concentrate adeno-associated virus at ulcer sites, reducing systemic liver toxicity.

Ligand-polar drug conjugates employ stable linkers to prevent premature payload release in circulation while ensuring rapid intracellular delivery.

Glycidol-based nanoparticles encapsulate hydrophobic drugs to resolve solubility trade-offs while maintaining therapeutic efficacy.

Chimeric compounds link venetoclax to Mcl-1 targeting moieties, restoring efficacy against resistant cancer cells.

Nucleic acid compounds with abasic nucleosides form stable complexes with RNA transcripts to suppress target gene expression.

A peptide-hydrogel composite forms a scaffold via phase transition to model articular cartilage properties.

Lipid-oligonucleotide conjugates form parallel G-quadruplex structures to stabilize micelles against premature disassembly in biological fluids.

A multivalent ligand binds to glutamine transporters on cancer cells.

A CARP-1-NEMO inhibitor blocks protein binding to halt cell growth and DNA repair pathways in cancer treatment.

Hoveyda-Grubbs catalyst drives cross-metathesis of cellulose esters with terminal olefins to yield soluble polysaccharide derivatives.

Polymer conjugates bind thyroid hormone antagonists via non-cleavable linkers to target integrin alpha v beta 3 receptors.

D-mannitol powder and granules compress to 30 N hardness for rapid oral disintegration.

Amide-linked polymer conjugates initiate atom transfer radical polymerization to form hydrophilic chains on biological molecules.

Conjugating a sub-optimal ligand to a nanobody targeting molecule resolves low binding affinity and specificity by forming a composite complex on the receptor.

Combines YAP/TAZ-TEAD and KRAS inhibitors to overcome resistance mechanisms and enhance treatment efficacy for cancers with Ras and Hippo pathway alterations.

Amphiphilic compound with polyol backbone reduces plastic adsorptivity while maintaining intracellular uptake efficiency.

Benzylidene protection enables recrystallization purification, narrowing molecular weight distribution and increasing yield.

Hyaluronic acid bioconjugates link antitumoral drugs via molecular spacers to target neoplastic cells, overcoming multi-drug resistance and systemic toxicity.

A beta-amino maleimide derivative enables stable antibody-payload conjugates via Michael addition and mild hydrolysis.